METHOD OF TREATMENT AND BIOASSAY INVOLVING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS CARDIAC-DERIVED MYOCARDIAL DEPRESSANT FACTOR

• Main Authors: MONTE WILLIS, THAIS SIELECKI, VIDAL DE LA CRUZ, BRETT GIROIR
• Format: Patent
• Language: English; Spanish
• Published: 23.05.2007
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor. Una modalidad de la presente invencion se refiere a una composicion farmaceutica, la cual incluye una cantidad efectiva terapeuticamente de al menos un anticuerpo anti-MIF; y al menos un portador aceptable. Otra modalidad de la presente invencion se refiere a una composicion farmaceutica, la cual incluye una cantidad efectiva terapeuticamente de al menos un anticuerpo anti-CD74; y el menos un portador aceptable farmaceuticamente. Otra modalidad de la presente invencion se refiere a otra composicion farmaceutica, la cual incluye una cantidad efectiva terapeuticamente de al menos un anticuerpo anti-TNFR, una cantidad efectiva terapeuticamente de al menos un anticuerpo anti-MIF, y al menos un portador aceptable farmaceuticamente. Otras modalidades de la presente invencion se refieren a metodos para tratar o prevenir una disfuncion cardiaca, cardiodepresion, disfuncion cardiaca asociada con lesiones por quemaduras, mejorar la funcion cardiaca en un sujeto en seguida de un infarto agudo al miocardio, e identificar un inhibidor del Factor Inhibidor de la Migracion de Macrofagos (MIF).